摘要
目的:分析注射用重组人组织型纤溶酶原激活剂(rt-PA)溶栓治疗高龄脑梗死患者中的应用价值。方法:选择接受治疗的高龄脑梗死患者178例,并随机分为观察组和对照组,每组89例。两组患者分别接受rt-PA溶栓治疗和阿司匹林及巴曲酶治疗,检测治疗前、后患者的神经功能缺损、肢体功能评分及不良治疗结局等情况。结果:1溶栓治疗前两组患者的神经功能缺损情况差异无统计学意义(t=0.372,P>0.05),接受治疗1 d、5 d和15 d后,观察组患者的神经功能缺损评分均明显低于对照组患者,差异有统计学意义(t=2.321,t=4.324,t=4.637;P<0.05);2接受治疗后观察组患者的肢体功能严重障碍患者人数明显少于对照组患者,肢体功能优于对照组患者,差异有统计学意义(u=4.821,P<0.05);3接受不同溶栓治疗后,观察组患者的再次脑梗死、大面积脑出血、植物生存及死亡等不良情况发生率均明显低于对照组患者,差异有统计学意义(u=4.392,u=5.136,u=6.293,u=8.392,P<0.05)。结论:注射用重组人组织型纤溶酶原激活剂溶栓治疗可显著优化患者的神经功能及肢体功能,降低治疗后不良情况发生率,具有积极的临床意义。
Objective： To analyze the Effect of rt-PA thrombolytic therapy on elderly patients with cerebral infarction. Methods： Chosen elderly patients with cerebral infarction between November 2012 to November 2013 as study object, randomly divided into observe group receive rt-PA thrombolytic therapy and control group receive aspirin and Batroxobin, detecting neurological impairment, physical function score and adverse treatment outcomes. Results： 1）before thrombolytic treatment, neurological deficit situation of two groups were no significant difference （P〉0.05）, after treatment, observation group patients’ neurological deficit scores were significantly lower than control group at each time point （P〈0.05）; 2）after treatment, limb function defective number of observation group patient was significantly less than observation group（P〈0.05）; 3）after treatment, observation groups’ adverse outcomes as again infarction, large area cerebral hemorrhage after thrombolysis, plant survival, incidence of death was significantly lower than control group （P〈0.05）. Conclusion： The injection of rt-PA thrombolytic therapy can significantly optimize neurological and physical function in patients , reducing the incidence of adverse treatment outcomes, with positive clinical significance.
出处
《中国医学装备》
2014年第12期136-139,共4页
China Medical Equipment
关键词
脑梗死
重组人组织型纤溶酶原激活剂
溶栓
高龄
Infarction
Recombinant tissue plasminogen activator
Thrombolysis
Advanced age
